protocolSection identificationModule nctId: NCT06353087, orgStudyIdInfo id: B7451114, briefTitle: Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry), acronym: ATTRACT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-11-15, completionDateStruct date: 2025-11-15, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics., conditionsModule conditions: Dermatitis, Atopic, conditions: Dermatitis, conditions: Eczema, conditions: Skin Diseases, conditions: Immune System Diseases, conditions: Janus Kinase Inhibitors, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: Percentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52, primaryOutcomes measure: Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 2, 12, 52, primaryOutcomes measure: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 2, 12, 52, secondaryOutcomes measure: Duration of Abrocitinib Treatment: All Participants, secondaryOutcomes measure: Demographic and baseline characteristics, secondaryOutcomes measure: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 12, 16, 24, and 52, secondaryOutcomes measure: Change From Baseline in Investigator's Global Assessment (IGA) at Weeks 2, 4, 12, 16, 24, and 52, secondaryOutcomes measure: Change From Baseline in Percentage Body Surface Area at Week 2, 4, 12, 16, 24, and 52, secondaryOutcomes measure: Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 2, 4, 12, and 52, secondaryOutcomes measure: Change from baseline of Atopic Dermatitis Control Tool (ADCT) score at Week 2, 4, 12, and 52, secondaryOutcomes measure: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score to Week 2, 4, 12, and 52, secondaryOutcomes measure: Change From Baseline in Patient Global Assessment (PtGA), secondaryOutcomes measure: Percentage Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 2, 4, 12, 16, 24, and 52, secondaryOutcomes measure: Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52, secondaryOutcomes measure: Percentage of Participants Achieving 0 or 1 in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52, eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False